Cargando…
Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial
INTRODUCTION: The long-term efficacy and safety of donepezil 10 mg in patients with dementia with Lewy bodies (DLB) were investigated in a 52-week Phase 3 trial. METHODS: This 52-week study consisted of 16-week randomized placebo-controlled (RCT) and 36-week open-label extension phases. Of 142 DLB p...
Autores principales: | Mori, Etsuro, Ikeda, Manabu, Nagai, Reiko, Matsuo, Kazutaka, Nakagawa, Masaki, Kosaka, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338564/ https://www.ncbi.nlm.nih.gov/pubmed/25713600 http://dx.doi.org/10.1186/s13195-014-0081-2 |
Ejemplares similares
-
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial
por: Ikeda, Manabu, et al.
Publicado: (2015) -
Donepezil for Dementia with Lewy Bodies: A Randomized, Placebo-Controlled Trial
por: Mori, Etsuro, et al.
Publicado: (2012) -
Aphasic mild cognitive impairment in prodromal dementia with Lewy bodies
por: Watanabe, Hiroyuki, et al.
Publicado: (2023) -
Primary Progressive Aphasia as a Prodromal State of Dementia With Lewy Bodies: A Case Report
por: Watanabe, Hiroyuki, et al.
Publicado: (2020) -
Lewy body disease and dementia with Lewy bodies
por: KOSAKA, Kenji
Publicado: (2014)